# Sandoz invests $183M in European antibiotic production expansion

Sandoz, a division of Novartis, will invest more than $122 million to add new technology at its Kundl, Austria plant to make oral amoxicillin API, and $61 million into its Palafolls site in Spain to increase penicillin production capacity. Production at the Les Franqueses site will be phased out by 2024.

- Type: Expansion
- Announced: 2021-05-20
- Where: Kundl, Austria, Austria
- Value: $122.0M
- Status: announced
- Products: oral amoxicillin, penicillin
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Sandoz](https://endata.com/companies/55313.md)
- [Novartis](https://endata.com/companies/32041.md) (partner)

## Sources

- [endpoints.news](https://endpoints.news/novartis-sandoz-reshuffles-antibiotic-supply-chain-in-eu-as-field-faces-a-shortage-of-investment/), 2021-05-20: "Sandoz will shuffle its antibiotic production in Europe by adding capabilities at two of its plants and phasing out manufacturing at another by 2024, the company said."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.